Teva scrambles to block approval for Biogen’s Copaxone rival

14.01.2013                      03.Schwat. 5773


Teva scrambles to block approval for Biogen's Copaxone rival

Files citizen's petition and warns that Biogen Idec itself revealed troubling information about potential side effects of MS therapy BG-12.

Teva Pharmaceutical Industries last month began an effort to block or at least delay the launch of a drug that would compete with its blockbuster drug Copaxone, an injectable treatment for multiple sclerosis. Teva filed a citizen's petition to prevent the U.S. Food and Drug Administration approving Biogen Idec's pill BG-12, also a therapy for multiple sclerosis, which is an incurable degenerative disease….